Hsuan-Ming Yao

3PUBLICATIONS
0CO-AUTHORS
PharmacogenomicsPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Oct 07, 2021
Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.

Hsuan-Ming Yao, Sarah Ruta Jones, Serafin Morales

|Jun 12, 2020
PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta®): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers.

Shahrzad Moosavi, Troy Borema, Reginald Ewesuedo

|Mar 23, 2019
PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen®): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers.

Hsuan-Ming Yao, Faith D Ottery, Troy Borema

Pageof 1

Frequent Collaborators